Corline Biomedical AB (CLBIO) - Total Assets
Based on the latest financial reports, Corline Biomedical AB (CLBIO) holds total assets worth Skr114.18 Million SEK (≈ $12.29 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Corline Biomedical AB - Total Assets Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's total assets have evolved over time, based on quarterly financial data. Also see Corline Biomedical AB (CLBIO) total market value for the company's overall valuation and market capitalisation.
Corline Biomedical AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Corline Biomedical AB's total assets of Skr114.18 Million consist of 24.3% current assets and 75.7% non-current assets. Review Corline Biomedical AB (CLBIO) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr20.56 Million | 20.9% |
| Accounts Receivable | Skr2.31 Million | 2.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr162.00K | 0.2% |
| Intangible Assets | Skr74.43 Million | 75.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CLBIO stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corline Biomedical AB's current assets represent 24.3% of total assets in 2025, a decrease from 28.8% in 2012.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, up from 18.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 75.5% of total assets.
Corline Biomedical AB Competitors by Total Assets
Key competitors of Corline Biomedical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Corline Biomedical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.48 | 2.09 | 11.85 |
| Quick Ratio | 6.26 | 2.09 | 11.85 |
| Cash Ratio | 0.00 | 1.44 | 11.40 |
| Working Capital | Skr33.20 Million | Skr6.30 Million | Skr40.89 Million |
Corline Biomedical AB - Advanced Valuation Insights
This section examines the relationship between Corline Biomedical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.18 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | Skr98.58 Million |
| Market Capitalization | $39.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Corline Biomedical AB's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Corline Biomedical AB's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Corline Biomedical AB (2012–2025)
The table below shows the annual total assets of Corline Biomedical AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr98.58 Million ≈ $10.61 Million |
+4.03% |
| 2024-12-31 | Skr94.76 Million ≈ $10.20 Million |
-5.34% |
| 2023-12-31 | Skr100.11 Million ≈ $10.77 Million |
-1.65% |
| 2022-12-31 | Skr101.78 Million ≈ $10.95 Million |
+0.12% |
| 2021-12-31 | Skr101.66 Million ≈ $10.94 Million |
+74.43% |
| 2020-12-31 | Skr58.28 Million ≈ $6.27 Million |
-8.58% |
| 2019-12-31 | Skr63.75 Million ≈ $6.86 Million |
+1.33% |
| 2018-12-31 | Skr62.91 Million ≈ $6.77 Million |
+22.34% |
| 2017-12-31 | Skr51.43 Million ≈ $5.53 Million |
+24.60% |
| 2016-12-31 | Skr41.27 Million ≈ $4.44 Million |
+65.13% |
| 2015-12-31 | Skr24.99 Million ≈ $2.69 Million |
+49.02% |
| 2014-12-31 | Skr16.77 Million ≈ $1.81 Million |
+21.92% |
| 2013-12-31 | Skr13.76 Million ≈ $1.48 Million |
+10.41% |
| 2012-12-31 | Skr12.46 Million ≈ $1.34 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent ha… Read more